ClinicalTrials.gg
CompletedNCT02667886Updated Oct 3, 2024Results posted

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

A Phase 1/2 interventional study of X4P-001 and axitinib in Clear Cell Renal Cell Carcinoma, sponsored by X4 Pharmaceuticals. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by X4 Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
321st of 1,008
74 · median 40
Started
2016
with 42 others
Phase 1/2
146 of 1,142
31 open now
Registered
614th of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 321st largest by enrollment of the 1,008 interventional ones that give a count, is one of 43 that started in 2016, is one of 146 in phase 1/2, and was the 614th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.

Read the detailed description

X4P-001 is an orally bioavailable C-X-C chemokine receptor type 4 (CXCR4) antagonist that has demonstrated activity in various tumor models. CXCR4 is the receptor for C-X-C chemokine ligand type 12 (CXCL12). CXCL12 has potent chemotactic activity for lymphocytes and myeloid-derived suppressor cells (MDSCs), and is important in homing of hematopoietic stem cells to the bone marrow. CXCR4 is also expressed and active on multiple types of human cancers, including clear cell Renal Cell Carcinoma (ccRCC), ovarian cancer, and melanoma, and increased expression of CXCR4 on tumor cells has been associated with significantly decreased overall participant survival.

Multiple observations implicate the CXCL12/CXCR4 axis in contributing to the lack (or loss) of tumor responsiveness to angiogenesis inhibitors (also referred to as "angiogenic escape"). In animal cancer models, interference with CXCR4 function has been demonstrated to disrupt the tumor microenvironment and unmask the tumor to immune attack by multiple mechanisms, including:

  • Eliminating tumor re-vascularization
  • Decreasing the infiltration of MDSCs
  • Increasing the ratio of cluster of differentiation 8+ (CD8+) T cells to T regulatory (Treg) cells

The hypothesis and evidence of published data support is that effective CXCR4 antagonism by X4P-001 would be of potential benefit in participants with advanced ccRCC and other cancers by multiple mechanisms:

  • Decreased recruitment of MDSCs, resulting in increased anti-tumor immune attack
  • Sustained decrease in neoangiogenesis and tumor vascular supply
  • Interference with the autocrine effect of increased expression by ccRCC of both CXCR4 and CXCL12, its only ligand, thereby, potentially reducing cancer cell metastasis

This initial clinical trial in participants with advanced ccRCC will evaluate X4P-001 both as a single agent (monotherapy) and also in combination with axitinib, a small molecule tyrosine kinase inhibitor (TKI) approved for second-line treatment of participants with ccRCC. This combination has the potential to further improve outcomes by reducing the angiogenic escape that typically occurs with TKI therapy.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of predominant ccRCC.
  • Have received at least one prior course of treatment for ccRCC. Part C only: Prior treatment must include at least 1 course of vascular endothelial growth factor (VEGF)-directed therapy.
  • Have on computed tomography (CT) imaging done within 28 days of Day 1 findings consistent with advanced ccRCC, including at least one extra-renal measurable target lesion meeting the criteria of (RECIST) Version 1.1.
  • For women of and men, agree to use effective methods from screening, through the study, and for at least 4 weeks after the last dose of study drug.
  • For women of childbearing potential, have a negative pregnancy test (serum or urine) on Day 1 prior to initiating study treatment.
  • Be willing and able to comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • Has of less than 3 months.
  • Has performance status Grade >2 ( [ECOG] criteria).
  • Has (NYHA) Class III or IV heart failure or uncontrolled hypertension (systolic blood pressure [SBP] ≥160 millimeters of mercury [mm Hg]; diastolic blood pressure [DBP] ≥100 mm Hg).
  • Has previously received X4P-001.
  • Parts A and B only: Has received a prior course of axitinib.
  • Parts A and B only: Has received mechanistic target of rapamycin (mTOR) inhibitor(s) as their only prior treatment for ccRCC.
  • Has a prior history or current evidence of intracranial (CNS) RCC, except for

    ≤3 lesions treated by CyberKnife or excisional surgery, clinically stable for at least 4 weeks, and without evidence of recurrence on MRI imaging at screening.

  • Has ongoing acute clinical adverse events National Cancer Institute (NCI CTCAE) Grade >1 resulting from prior cancer therapies (except alopecia, tyrosine kinase inhibitor [TKI]-related hand-foot syndrome, or thyroid dysfunction).
  • Has had within the past 6 months the occurrence or persistence of one or more of the following medical conditions that could not be controlled with usual medical care (for example, required emergency care or hospitalization): hypertension, angina, congestive heart failure, diabetes, seizure disorder.
  • Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (CTC Grade 3 or 4), chronic liver disease (meeting criteria for Class B or C), a second active (excluding basal cell carcinoma and cervical carcinoma in situ), organ transplantation.
  • Has had within the 4 weeks prior to initiation of study drug, or is expected to have during the study period, surgery requiring general anesthesia.
  • Has, at screening, serologic laboratory tests meeting one or more of the following criteria:
  • An indeterminate or positive test for antibody to (HIV)-1 or -2.
  • An indeterminate or positive test for antibody to virus (HCV), unless documented to have no detectable viral load on two independent samples.
  • A positive test for surface antigen (HBsAg).
  • Has, at screening, safety laboratory tests meeting one or more of the following criteria:
  • \<8.0 grams (g)/deciliter (dL)
  • (ANC) \<1,500/microliter (μL)
  • \<75,000/μL
  • Creatinine >2.0x (ULN)
  • Serum (AST) >2.5x ULN
  • Serum alanine transaminase (ALT) >2.5x ULN
  • Total >1.5x ULN (unless due to Gilbert's Syndrome)
  • (INR) >1.5x ULN
  • Has received other anti-cancer therapy within the following specified intervals prior to Day 1:
  • TKI within 2 weeks.
  • Radiation therapy within 2 weeks.
  • Bevacizumab within 4 weeks.
  • Other chemotherapy (for example, mitomycin-C, nitrosourea) or immunotherapy (for example, antibody, cytokine) within 4 weeks
  • For anti-cancer therapies, the interval will be determined in consultation with the Medical Monitor.
  • Has, within 2 weeks prior to Day 1, received a medication prohibited based on cytochrome P3A4 () interaction
  • Has, within 2 weeks prior to Day 1, received systemic exceeding prednisone 10 mg per day or equivalent; for other agents, the exclusionary dose and duration will be determined in consultation with the Medical Monitor.
  • Is, within 2 weeks prior to Day 1, nursing.
  • Has, at the planned initiation of study drug, an uncontrolled infection.
  • Has any other medical or personal condition that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the participant, or may preclude the participant's successful completion of the clinical trial.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Dose Escalation (Part A): X4P-001 200 mg BID with Axitinib

    Participants will receive X4P-001 200 milligrams (mg) orally twice daily (BID) with axitinib at 5 mg orally BID.

    Drug: X4P-001 · Drug: axitinib

  • Experimental
    Dose Escalation (Part A): X4P-001 400 mg QD with Axitinib

    Participants will receive X4P-001 400 mg orally once daily (QD) with axitinib at 5 mg orally BID.

    Drug: X4P-001 · Drug: axitinib

  • Experimental
    Dose Escalation (Part A): X4P-001 600 mg QD with Axitinib

    Participants will receive X4P-001 600 mg orally QD with axitinib at 5 mg orally BID.

    Drug: X4P-001 · Drug: axitinib

  • Experimental
    Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib

    Participants received X4P-001 400 mg orally QD with axitinib at 5 mg orally BID.

    Drug: X4P-001 · Drug: axitinib

  • Experimental
    Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy

    Participants will receive X4P-001 600 mg orally QD.

    Drug: X4P-001

Interventions

  • Continuous, oral dosing

    Also known as: Mavorixafor, AMD11070

  • Continuous, oral dosing

    Also known as: Inlyta

06

What researchers measure

Primary outcomes

  1. Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. Adverse events with onset after administration of the first dose of study drug up to 10 days after last dosing date were considered TEAEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: From first dose of study drug up to 10 days after last dosing (maximum exposure: 52.1 months)

Secondary outcomes

  1. Parts A and B: Objective Response Rate (ORR), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    The ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 millimeters (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From administration of first dose of study medication until disease progression, study completion or early termination (up to 80 weeks)

  2. Parts A and B: Time to Objective Response, as Assessed Using RECIST v1.1

    Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever came first. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From administration of first dose of study medication until first appearance of CR or PR (up to 80 weeks)

  3. Parts A and B: Duration of Objective Response (DOR), as Assessed Using RECIST v1.1

    The DOR was defined as the time from first CR or PR whichever came first until the time of disease progression or death by any cause. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

    Time frame: Time from first CR or PR until the time of disease progression or death due to any cause (up to 80 weeks)

  4. Parts A and B: Disease Control Rate (DCR), as Assessed Using RECIST v1.1

    The DCR was defined as the percentage of participants with best overall response of CR, PR or stable disease (SD). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

    Time frame: From administration of first dose of study medication until disease progression, study completion or early termination (up to 80 weeks)

  5. Parts A and B: Time to Progression (TTP), as Assessed Using RECIST v1.1

    The TTP was defined as the time from first administration of combination regimen until PD. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

    Time frame: From administration of first dose of study medication until disease progression (up to 80 weeks)

  6. Parts A and B: Progression Free Survival (PFS), as Assessed Using RECIST v1.1

    The PFS was defined as the time from first administration of combination regimen until disease progression or death from any cause. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

    Time frame: From administration of first dose of study medication until disease progression or death from any cause (up to 80 weeks)

  7. Parts A and B: Maximum Plasma Concentration (Cmax) of X4P-001

    Time frame: Day 1 and Day 15 of Cycle 1

  8. Area Under the Curve From Time 0 to the Last Quantifiable Timepoint (AUC0-tlast)

    Time frame: Day 1 and Day 15 of Cycle 1

07

Results

Posted Aug 14, 2024

Participant flow

Dose Escalation (Part A)
Participant flow — Dose Escalation (Part A)
MilestoneDose Escalation (Part A): X4P-001 200 mg BID With AxitinibDose Escalation (Part A): X4P-001 400 mg QD With AxitinibDose Escalation (Part A): X4P-001 600 mg QD With AxitinibDose Expansion (Part B): X4P-001 400 mg QD With AxitinibDose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy
Started37600
Received at least 1 dose of study drug37600
Completed10000
Not completed27600
Withdrew: Adverse event13100
Withdrew: Disease progression14300
Withdrew: Dose-limiting toxicity (dlt)00200
Dose Expansion (Part B)
Participant flow — Dose Expansion (Part B)
MilestoneDose Escalation (Part A): X4P-001 200 mg BID With AxitinibDose Escalation (Part A): X4P-001 400 mg QD With AxitinibDose Escalation (Part A): X4P-001 600 mg QD With AxitinibDose Expansion (Part B): X4P-001 400 mg QD With AxitinibDose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy
Started000550
Received at least 1 dose of study drug000550
Completed00010
Not completed000540
Withdrew: Adverse event00090
Withdrew: Clinical deterioration00030
Withdrew: Disease progression000380
Withdrew: Withdrawal by subject00040
Dose Escalation and Expansion (Part C)
Participant flow — Dose Escalation and Expansion (Part C)
MilestoneDose Escalation (Part A): X4P-001 200 mg BID With AxitinibDose Escalation (Part A): X4P-001 400 mg QD With AxitinibDose Escalation (Part A): X4P-001 600 mg QD With AxitinibDose Expansion (Part B): X4P-001 400 mg QD With AxitinibDose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy
Started00003
Received at least 1 dose of study drug00003
Completed00000
Not completed00003
Withdrew: Adverse event00001
Withdrew: Dlt00002

Outcome measures

PrimaryParts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. Adverse events with onset after administration of the first dose of study drug up to 10 days after last dosing date were considered TEAEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
From first dose of study drug up to 10 days after last dosing (maximum exposure: 52.1 months)
Reported as:
Count of participants · Participants
Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With AxitinibX4P-001 600 mg QD Monotherapy
Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)36263
SecondaryParts A and B: Objective Response Rate (ORR), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

The ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 millimeters (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From administration of first dose of study medication until disease progression, study completion or early termination (up to 80 weeks)
Reported as:
Number · percentage of participants
Parts A and B: Objective Response Rate (ORR), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentage of participantsX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With Axitinib
Parts A and B: Objective Response Rate (ORR), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.166.7 (9.4 to 99.2)27.1 (16.4 to 40.3)
SecondaryParts A and B: Time to Objective Response, as Assessed Using RECIST v1.1

Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever came first. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From administration of first dose of study medication until first appearance of CR or PR (up to 80 weeks)
Reported as:
Median · months
Parts A and B: Time to Objective Response, as Assessed Using RECIST v1.1
monthsX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With Axitinib
Parts A and B: Time to Objective Response, as Assessed Using RECIST v1.112.9 (1.9 to NA)14.6 (12.9 to NA)
SecondaryParts A and B: Duration of Objective Response (DOR), as Assessed Using RECIST v1.1

The DOR was defined as the time from first CR or PR whichever came first until the time of disease progression or death by any cause. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

Time frame:
Time from first CR or PR until the time of disease progression or death due to any cause (up to 80 weeks)
Reported as:
Median · months
Parts A and B: Duration of Objective Response (DOR), as Assessed Using RECIST v1.1
monthsX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With Axitinib
Parts A and B: Duration of Objective Response (DOR), as Assessed Using RECIST v1.1NA (9.2 to NA)16.6 (10.8 to 36.0)
SecondaryParts A and B: Disease Control Rate (DCR), as Assessed Using RECIST v1.1

The DCR was defined as the percentage of participants with best overall response of CR, PR or stable disease (SD). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

Time frame:
From administration of first dose of study medication until disease progression, study completion or early termination (up to 80 weeks)
Reported as:
Number · percentage of participants
Parts A and B: Disease Control Rate (DCR), as Assessed Using RECIST v1.1
percentage of participantsX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With Axitinib
Parts A and B: Disease Control Rate (DCR), as Assessed Using RECIST v1.1100.0 (29.2 to 100.0)71.2 (57.9 to 82.2)
SecondaryParts A and B: Time to Progression (TTP), as Assessed Using RECIST v1.1

The TTP was defined as the time from first administration of combination regimen until PD. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

Time frame:
From administration of first dose of study medication until disease progression (up to 80 weeks)
Reported as:
Median · months
Parts A and B: Time to Progression (TTP), as Assessed Using RECIST v1.1
monthsX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With Axitinib
Parts A and B: Time to Progression (TTP), as Assessed Using RECIST v1.111.1 (5.5 to NA)7.4 (5.6 to 14.7)
SecondaryParts A and B: Progression Free Survival (PFS), as Assessed Using RECIST v1.1

The PFS was defined as the time from first administration of combination regimen until disease progression or death from any cause. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

Time frame:
From administration of first dose of study medication until disease progression or death from any cause (up to 80 weeks)
Reported as:
Median · months
Parts A and B: Progression Free Survival (PFS), as Assessed Using RECIST v1.1
monthsX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With Axitinib
Parts A and B: Progression Free Survival (PFS), as Assessed Using RECIST v1.111.1 (5.5 to NA)7.4 (5.5 to 12.5)
SecondaryParts A and B: Maximum Plasma Concentration (Cmax) of X4P-001
Time frame:
Day 1 and Day 15 of Cycle 1
Reported as:
Geometric mean · nanograms (ng)/milliliter (mL)
Parts A and B: Maximum Plasma Concentration (Cmax) of X4P-001
nanograms (ng)/milliliter (mL)X4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With Axitinib
Day 11070 ± 59.53130 ± 67.24170 ± 42.7
Day 15831 ± 8.203710 ± 73.53900 ± 39.2
SecondaryArea Under the Curve From Time 0 to the Last Quantifiable Timepoint (AUC0-tlast)
Time frame:
Day 1 and Day 15 of Cycle 1
Reported as:
Geometric mean · hours*ng/mL
Area Under the Curve From Time 0 to the Last Quantifiable Timepoint (AUC0-tlast)
hours*ng/mLX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With Axitinib
Day 12200 ± 62.86790 ± 80.29830 ± 54.3
Day 153000 ± 26.413100 ± 90.715100 ± 44.3

Adverse events

Collected over From first dose of study drug up to 10 days after last dosing (maximum exposure: 52.1 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
X4P-001 200 mg BID With Axitinib1/3 (33.3%)1/3 (33.3%)3/3 (100%)
X4P-001 400 mg QD With Axitinib2/62 (3.2%)26/62 (41.9%)62/62 (100%)
X4P-001 600 mg QD With Axitinib1/6 (16.7%)1/6 (16.7%)6/6 (100%)
X4P-001 600 mg QD Monotherapy3/3 (100%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With AxitinibX4P-001 600 mg QD Monotherapy
NauseaGastrointestinal disorders1/30/620/60/3
Acute kidney injuryRenal and urinary disorders0/30/621/61/3
HyperglycemiaMetabolism and nutrition disorders0/30/620/61/3
DiarrheaGastrointestinal disorders0/32/621/60/3
PainGeneral disorders0/32/620/60/3
HyperkalaemiaMetabolism and nutrition disorders0/32/620/60/3
HypertensionVascular disorders0/32/620/60/3
Abdominal painGastrointestinal disorders0/31/620/60/3
Abdominal distensionGastrointestinal disorders0/31/620/60/3
AscitesGastrointestinal disorders0/31/620/60/3
Most frequent other events
Showing 10 of 274
Most frequent other events
EventX4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With AxitinibX4P-001 600 mg QD Monotherapy
DiarrhoeaGastrointestinal disorders3/333/623/61/3
FatigueGeneral disorders3/330/625/62/3
Abnormal loss of weightMetabolism and nutrition disorders3/32/621/60/3
HeadacheNervous system disorders3/313/621/60/3
HypertensionVascular disorders3/324/623/60/3
NauseaGastrointestinal disorders2/322/623/62/3
VomitingGastrointestinal disorders2/320/621/60/3
ConstipationGastrointestinal disorders2/312/620/62/3
Weight decreasedInvestigations1/328/620/62/3
Non-cardiac chest painGeneral disorders2/36/620/60/3

Baseline characteristics

Safety population included all participants who received at least 1 dose of study drug. As planned, Baseline Characteristics data collected per dose level not per study part.

Age, Customized
Age, Customized(Participants)X4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With AxitinibX4P-001 600 mg QD MonotherapyTotal
16-64 Years3374145
≥65 Years0252229
Sex: Female, Male
Sex: Female, Male(Participants)X4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With AxitinibX4P-001 600 mg QD MonotherapyTotal
Female0100212
Male3526162
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)X4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With AxitinibX4P-001 600 mg QD MonotherapyTotal
Hispanic or Latino07007
Not Hispanic or Latino3556367
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)X4P-001 200 mg BID With AxitinibX4P-001 400 mg QD With AxitinibX4P-001 600 mg QD With AxitinibX4P-001 600 mg QD MonotherapyTotal
American Indian or Alaska Native00000
Asian0170017
Native Hawaiian or Other Pacific Islander00000
Black or African American02002
White3406352
More than one race00000
Unknown or Not Reported03003
08

Study locations

20 sites
  • Scottsdale, Arizona 85259, United States
  • Washington, District of Columbia 20057, United States
  • Jacksonville, Florida 32224, United States
  • Chicago, Illinois 60637, United States
  • Indianapolis, Indiana 46237, United States
  • Iowa City, Iowa 52242, United States
  • New Orleans, Louisiana 70121, United States
  • Boston, Massachusetts 02215, United States
  • Detroit, Michigan 48201, United States
  • Saint Paul, Minnesota 55101, United States
  • Saint Louis, Missouri 63110, United States
  • Hackensack, New Jersey 07601, United States
  • Bronx, New York 10461, United States
  • New York, New York 10029, United States
  • Toledo, Ohio 43623, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Greenville, South Carolina 29605, United States
  • Houston, Texas 77030, United States
  • Gyeyang-gu, Seoul 06351, Korea, Republic of
  • Seongdu, Seoul 03722, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Apr 2022, 71 months.

Results were first posted in Aug 2024, 2 years 4 months after primary completion. A results delay was requested in Mar 2023.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 71 months is close to that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2016
First posted
Jan 29, 2016
StartActual
Apr 27, 2016
Primary completionActual
Apr 14, 2022
CompletionActual
Apr 14, 2022
Results delay requested
Mar 17, 2023
Results first posted
Aug 14, 2024
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02667886
Lead sponsor
X4 Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 29, 2016
Start date
Apr 27, 2016
Primary completion
Apr 14, 2022
Completion
Apr 14, 2022
Results posted
Aug 14, 2024
Last update
Oct 3, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mavorixafor

Start the discussion